LXRP News and Press, Lexaria Bioscience Corp. From 10/21/20

Lexaria Bioscience (LXRP) receives its first-ever granted patent in Europe related to its DehydraTECHTM technology. European patent number 3164141 will be published in the European Patent Bulletin of November 11, 2020 entitled "Food and Beverage Compositions Infused With Lipophilic Activ...

New patent includes method of treatment claims for a broad range of disease conditions including use of: cannabinoids to treat cardiac conditions such as hypertension and neurological diseases such as Alzheimer's and Parkinson's cannabinoids to treat metabolic disorders and subst...

(TheNewswire) New patent includes method of treatment claims for a broad range of disease conditions including use of: - cannabinoids to treat cardiac conditions such as hypertension and neurological diseases such as Alzheimer's and Parkinson's - cannabinoids...

(TheNewswire) Kelowna, British Columbia - October 9, 2020 - Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms updates the status of the business relationship between A...

Lexaria Bioscience (LXRP) has received a conditional approval from the Human Research Ethics Committee in addition to government regulatory approval to conduct a pilot study in healthy volunteers of antiviral drugs that have previously been studied against coronavirus strains other than ...

Company Raises Commitment to Antiviral Research with Launch of Rodent Antiviral Drug Delivery Study with Potential COVID-19 Applications KELOWNA, BC / ACCESSWIRE / September 29, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in dr...

(TheNewswire) Company Raises Commitment to Antiviral Research with Launch of Rodent Antiviral Drug Delivery Study with Potential COVID-19 Applications Kelowna, British Columbia - TheNewswire - September 29, 2020 - Lexaria Bioscience Corp. (OTC:L...

Lexaria Bioscience (LXRP) has received purchase-order commitments for ~4.4M CBD servings of its patented DehydraTECHTM enabled CBD powders.The order to be processed during the Company's fiscal Q1 2021 which ends November 30, 2020.The company has also received verbal requests from existing lic...

KELOWNA, BC / ACCESSWIRE / September 23, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CNSX:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it is in receipt of purchase-order commitments for approximately 4.4 million CBD servings o...

Lexaria Bioscience (LXRP) has been granted U.S. Patent No. 10,756,180, entitled "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof".This new patent provides patent claims that protect the use of Lexaria's DehydraTECH technology together with ...